Trevi Therapeutics, Inc.
TRVI
$13.35
$0.050.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 33.81% | 32.59% | 17.96% | 20.70% | 5.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.21% | 3.26% | -3.66% | 37.05% | 55.74% |
| Operating Income | 1.21% | -3.26% | 3.66% | -37.05% | -55.74% |
| Income Before Tax | 10.97% | 0.31% | 5.12% | -46.08% | -72.13% |
| Income Tax Expenses | 51.61% | -162.50% | -37.50% | -11.11% | -138.46% |
| Earnings from Continuing Operations | 10.87% | 0.41% | 5.16% | -45.95% | -72.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.87% | 0.41% | 5.16% | -45.95% | -72.02% |
| EBIT | 1.21% | -3.26% | 3.66% | -37.05% | -55.74% |
| EBITDA | 1.23% | -3.27% | 3.69% | -37.17% | -55.95% |
| EPS Basic | 37.80% | 22.75% | 19.73% | -37.02% | -68.65% |
| Normalized Basic EPS | 37.85% | 22.75% | 19.71% | -37.14% | -68.87% |
| EPS Diluted | 37.80% | 22.75% | 19.73% | -37.02% | -68.65% |
| Normalized Diluted EPS | 37.85% | 22.75% | 19.71% | -37.14% | -68.87% |
| Average Basic Shares Outstanding | 43.27% | 29.01% | 18.18% | 6.56% | 1.97% |
| Average Diluted Shares Outstanding | 43.27% | 29.01% | 18.18% | 6.56% | 1.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |